Skip to main content
Zanubrutinib elicits favorable long-term responses in relapsed or refractory CLL or SLL
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Zanubrutinib elicits favorable long-term responses in relapsed or refractory CLL or SLL
User login
Username
Password
Reset your password
Concept
Lead
score
Non-Hodgkin Lymphoma (NHL)
1
1
Tyrosine Kinase Inhibitor
0
1
Refractory
0
0.86
Lymphoma
0
0.51
Specialty
Lead
score
Hematology-Oncology
1
1
Edit Tags